TrialDiabetes, obesity & metabolism2014

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

J Bolinder et al.PubMed ↗Publisher ↗

No numbers read from the abstract.